Keeping up with Counterfeiters: The Battle Against Counterfeit Medical Devices
What do you think of when you hear about counterfeit goods—a fake Rolex or a copy designer handbag? Poorly replicated luxury goods cause chaos and generate large profits for counterfeiters, but the real issues lie in plagiarized medical devices, not purses.
It is widely acknowledged that counterfeiting medical devices is a very real and constant threat to patient safety. With the forthcoming implementation of the EU Medical Device Regulation in 2020, there is an increase in demand for more information about product origin. This impending law will have a significant impact throughout the healthcare industry, affecting operations from one end of the supply chain to the other, from manufacturing to distribution.
With anti-Counterfeiting also come effective anti-diversion processes. While we need to ensure the product has not been replicated, we also need to ensure the product has not been removed from the supply chain, tampered with and then re-entered at a different continent, country and/or location.
This column discusses the key issues with counterfeit medical devices and provides recommendations to save money and reduce risk within your supply chain.
Anti-counterfeit measures protect both the manufacturer and the end user. In the life sciences industry and particularly, medical devices, a counterfeit item, when used, puts the patient at risk and impacts the manufacturer through potential damage to reputation, cost of removing these counterfeit goods out of the supply chain and additional effort to prevent further issues occurring. So, it is crucial that medical device manufacturers ensure their packaging, labeling, and supply chain is tight and precisely tracked to the point of use.
The second term we use is anti-diversion. This is to ensure that products that have been developed for a specific market, perhaps with materials that are not allowed in other countries but are authorized for the intended market, validated, compliant and fit for purpose, are not removed from the supply chain, repackaged and sent into a country that should not receive that item. It can be potentially dangerous for patients and is illegal. Therefore, the challenge is to avoid both counterfeit and diverted products.
How can I assure my medical device at the point of use or point of receipt is the right one? Manufacturers have both passive and active methods of clarification and protection.
The Passive Method
Passive methods apply to the packaging. Medical devices usually have three levels of packaging: The primary packaging (pouch), which then goes into a secondary box (product box) and finally packaged into a shipper where there will be multiple products stored in one package.
To avoid counterfeiting, manufacturers can apply deterrents to each of these items of packaging. Whether that be a hologram, UV identification code, 2-D barcode with unique numbering/serialization or hidden text printed using security or magnetic ink. These are not intended as end-user checks but as deterrents to the counterfeiter. A trained person can quickly establish if the product is authentic and can take things further by referencing the unique numbers used in the security marking via an authentication site.
The Active Method
The active method takes the passive method one step further, using various technologies to avert counterfeiting.
A unique serial number or reference number (URN) is a randomized number printed onto the product’s packaging and as it’s unique, it can be used to define exactly who manufactured the item, where it was manufactured and the country of origin. This type of serialization at the item level is vital in the fight against counterfeiting. Web-based “labeling and data management” solutions can support you in delivering secure printing for mass serialization to protect the product and the consumer. Serialization not only gives the ability to authenticate the product as genuine, but also offers the ability to track product movement throughout the supply chain, improve efficiency and most importantly, protect the end user.
Modern technologies can then use the serialized data in barcode format, which can be scanned at any point throughout the supply chain and checked with online systems to verify its authenticity. If the look-up comes back with no read/duplicate, then we know there is an issue with the product and it can be rejected out of the supply chain and additional action taken to remove additional counterfeit devices. These methods clearly work, are simple and cost-effective to implement.
Taking things further and linking logistics systems with the serialization detail can give a “smart” active method system that would look for activities and trends based on knowing which serial numbers were assigned to what product, to be sold in a which territory. For example, if a shipment of product with serial numbers assigned to the China market were scanned at a customer site in South America, this would be captured as a diverted product and flagged up to the manufacturer/supplier accordingly to engage and investigate.
It is therefore a combination of both passive and active methods that ensure true safety of counterfeiting items.
International Challenges
Destination labeling or just-in-time labeling is where products are predominantly manufactured with a single language printed label along with the product name and production variables. Traditionally, a product label would carry four or five additional languages on the packaging, along with an Instructions for Use (IFU) booklet that would contain every language where the product is approved for use. By law, the manufacturer has to print and ship the product with all the languages that may use it, which could be anything up to about 60 different languages, so region-specific labeling takes place to lessen the quantity of languages used on the label, which may take the number used, back down to five or six.
In the medical device industry today, consumers want the label to show just their local language or languages. With just-in-time labeling, you can develop a product label solution linked to orders received and use the end destination to drive the language(s) to be printed on the label and rather than use a pre-printed, large and expensive IFU booklet, print a single sheet containing the same languages as the label at the same time as the label is printed. This approach offers great flexibility, shorter time to market and huge cost savings linked to the elimination of the expensive IFU booklets.
If an item located in a regional distribution center needs to be redirected to a different market to that originally packaged and labeled, it will require a degree of repackaging, and this activity may be prone to risk of a counterfeited product being introduced into the supply chain. In any re-packing and re-labelling operation away from the manufacturer’s site and outside the manufacturer’s control, the important serialization data and other security measures can be lost, not replicated correctly or replaced with incorrect/cloned data to support the counterfeiter’s operation. It is at these smaller distribution hubs or sites where the re-packing takes place and the risk is highest for the introduction of counterfeited good into the supply chain.
By nature, if that product is labeled in Spanish and English, but needs to go to China, you would normally take off all the language-specific packaging and repackage with the corresponding language(s). But with the removal of these discrete codes, serialization and barcodes, we are removing and throwing away imperative security measures. Medical device companies are now installing controlled third-party print stations in warehouses to ensure local distributors are repackaging and re-labeling the product in a controlled way, the local language labels retain the serialization data, are printed with the local language approved design and format and any tracked field such as the unique serial number is carried over and the re-labelling event written back to the manufacturer’s global audit log.
Regional redirection then becomes part of the supply chain infrastructure and controlled accordingly. You will still be able to see the re-labeled item in the system, validated as authentic at a checkpoint, and re-labeled to the right destination market supported by the track and trace audit log. So, if re-labeling is taking place, with the right holistic approach and right controls, risk of counterfeit items entering the supply chain is reduced. Ideally, if you implement a just-in-time destination labeling solution at the point of manufacture, you can remove the need to re-label the solution out in the field and ensure it is securely delivered to the right destination in a shorter time frame.
Conclusion
Organizations need to make sure that they put into practice the correct systems and processes that can support them in meeting global standards and country-specific requirements now and in the future. Implementing a fit-for-purpose validated labeling solution with in-built serialization capabilities, which can provide very high volumes of unique, secured and “intelligent” serial numbers for this process would therefore be vital.
Control your label, its design, and the data to reduce risk. If you don’t have control of these three things, it’s likely that counterfeiting can creep in. Keeping up with counterfeiters in the life sciences industry is no easy task, but patients’ lives depend on it.
Related Articles
-
A global pandemic is still upon us, but that certainly does not mean that healthcare technology innovation is standing still. To help the medical device industry look to the future and prepare, experts from regulation and academia alike are bringing…
-
At Device Talks Boston in May, Ronald Kurz, Sr. Director and GM at Canon Virginia, Kathryn Unger, Sr. Mgr. of Global ESG Communications at Boston Scientific, and David Ettl, COO at Gradian Health System, addressed the question, how can we…
-
In addition to challenges brought by new EU MDR, Switzerland has struggled to approve and introduce new devices due to its revised national medical device ordinance, which created even tougher import hurdles.
-
“This report validates the broad applicability—and true value—of computational modeling and simulation as a critical engineering discipline. Tangible cost, quality and performance improvements are being realized by the early adopters.”
